We’ve spent a fair bit of time here on Street Register talking about Cannabis Science Inc (OTCMKTS: CBIS) in 2017, beginning in early January, while the stock was trading for less than six cents a share, through to its meteoric rise to a high of .1395 later that month (+163%). We continued to follow as it pulled back and underwent a dip-and-rip pattern which carried it from .075 and back to .1365, an added 82% swing.
Since that time, CBIS stock has once again undergone consolidation, but has found a solid level of support around the .08-area. This has coincided with an unmistakable bullish indicator on the chart, with the MACD converging toward a bullish cross, and the histogram ready to flip up to the bullish side. While this is not a guarantee of another forthcoming run, it is certainly an indicator which has been generally reliable in the past.
With that in mind, we want to take an opportunity to examine some of the current prevailing wisdom on the science behind Cannabis Science Inc (OTCMKTS: CBIS), which develops novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory.
Along from cancer, for which CBIS is actively involved in the research for novel cannibinoid treatments, one of those illnesses is Chronic Obstructive Pulmonary Disease (COPD), which is among those ailments that researchers believe cannabinoids can provide solutions for that may supersede the effectiveness of current treatments.
According to the Lung Institute, the symptoms of COPD are brought about by acute inflammation of the airways, obstructing and inhibiting normal breathing. In treating COPD, medications such as inhalers and corticosteroids work as anti-inflammatory agents reducing inflammation and dilating the respiratory airways. However, these forms of medication can be expensive over time and often come with negative side-effects from weight gain, blood sugar imbalance, and infection.
Recently it has been found that medical marijuana and its reported efficacy in treating respiratory illness has been linked to anti-inflammatory and broncho-dilative properties, as well as pain relief and potential immune system support. The catch-22 comes in the fact that it is detrimental to inhale the smoke of burning or vaporized organic material of any kind. That’s where companies like Cannabis Science come in, with their research in cannabinoids, which are beneficial compounds contained within the cannabis plant. These can be harnessed and delivered in such a way as to receive their benefits without the harm of smoking.
Recently, Cannabis Science reported that it had received a multitude emails inquiring about the timing of clinical research and the availability of treatment options, including for COPD. It had entered them into its in-house database and intends to respond to those inquiries when observational study officially commences on the disorder. The studies will include some of the over 500 cannabinoids that have been isolated and identified from cannabis. (Source:Marketwired)
On the downside, we don’t have a specific timeline on when those studies might yield more details. But we are going to be very interested in tracking Cannabis Science for both the potential of future developments there, and their effects on CBIS stock, but also from a technical standpoint. At present, there has been a notable buzz in the investment community about the prospects of seeing another leg-up on the CBIS chart. We’ll be sure to stay hot on its heels and stay up to date on everything that’s going on with this big player in the cannabis sector. Stay up to date with any and all new developments on CBIS right here at Street Register! All you have to do is sign up for our 100% free small cap newsletter! Just enter your active address in the box below and submit!